Labiotech.eu

RNA editing in humans: the race begins with first successful trial

8 days ago

By Roohi Mariam Peter

Spatial Transcriptomics: A window into disease

6 hours ago

By Sudha Sundaram

Could next-generation "switchable" CAR-T cells help improve the safety and efficacy of CAR-T therapies?

13 hours ago

By Willow Shah-neville

GPCR therapies: Eight promising biotechs hacking the cell signaling pathway

2 days ago

By Roohi Mariam Peter

Fighting severe epilepsies: A new era for Dravet syndrome treatment?

7 days ago

By Jules Adam

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

7 days ago

By Philip Hemme

The AI boom in cancer: Game-changer or just hype?

13 days ago

By Jules Adam

The future of epilepsy treatment: pioneering advances and patient-centric care

16 days ago

By Angelini Pharma

Eight nanotechnology companies to watch out for

9 days ago

By Roohi Mariam Peter

Top six European biotech entrepreneurs to know in 2024 (according to VCs)

14 days ago

By Roohi Mariam Peter

JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

15 days ago

By Willow Shah-neville

Europe's leading Biotech News Website

24 days ago

The biggest private biotech investments in September 2024

27 days ago

By Willow Shah-neville

Sublingual delivery of GLP-1 receptor agonists

29 days ago

Six biotechs driving progress in Duchenne muscular dystrophy

28 days ago

By Roohi Mariam Peter

Six biomimicry biotech companies harnessing nature's wisdom to develop breakthrough drug candidates

17 days ago

By Willow Shah-neville

Resolution Therapeutics raises $85 million to advance its macrophage therapy

28 days ago

By Jules Adam

The race for a bird flu vaccine: milestones and breakthroughs

Sep 30

By Roohi Mariam Peter

Pink crisis, clear solution: how advanced mass spectrometry turned a manufacturing risk into success

Sep 24

How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market

Sep 25

By Jennifer Tsang

Harnessing the body’s natural targeted protein degradation system to treat diseases

Sep 27

Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders

Sep 27

By Roohi Mariam Peter

New partnership model on the rise: how VCs are helping Pharma hunt for their next blockbuster

Sep 24

By Monica Karpinski

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses

Sep 23

By Jules Adam

Mitigating hot flashes: new therapies for menopause on the rise

Sep 20

By Roohi Mariam Peter

Two targets, one solution: The rise of bispecific antibodies

Sep 18

By Willow Shah-neville

Estonia's biobank: Is this the first large-scale personalized medicine initiative?

Sep 20

The crucial role of GS-CHO innovation in biopharmaceutical progress

Sep 3

By Alexander Burik

The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond

Sep 26

By Jules Adam

ADCs that deliver: The secret lies in rigorous characterization

Sep 18

By Ute Boronowsky

Mitochondrial disease treatments: is a breakthrough on the horizon?

Sep 19

By Roohi Mariam Peter

Can Europe revive its biopharma innovation leadership?

Sep 11

By Jules Adam

Targeting inflammation: A revolution in disease treatment

Sep 13

Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration

Sep 2

By Jules Adam

New treatments being developed for schizophrenia

Sep 12

By Roohi Mariam Peter

The therapeutic potential of circular RNA: Could it soon trump mRNA technology?

Aug 9

By Willow Shah-neville

2024: a year of breakthroughs for endometrial cancer?

Sep 4

By Roohi Mariam Peter

The power of tumor infiltrating lymphocytes to fight melanoma

Sep 6

The biggest private biotech investments in July 2024

Aug 6

By Willow Shah-neville

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies

Jul 26

By Jules Adam

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

Sep 6

By Jules Adam

The future of inflammatory bowel disease treatment: what is on the horizon?

Jul 25

By Roohi Mariam Peter

Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals

Jul 15

By Willow Shah-neville

[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA

Aug 9

Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?

Jul 24

By Willow Shah-neville

Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market

Sep 11

By Willow Shah-neville

The ABC of biotech partnerships: Understanding key types

Jul 19

By Willow Shah-neville

European regulators reject Alzheimer’s drug Leqembi: is it downhill from here?

Aug 1

By Roohi Mariam Peter

Participate in the 2024 Labiotech Reader Survey for a chance to win a €250 or $250 Amazon gift card!

Aug 26

By Aurore Michelin

Skin disease Archives

Apr 12

There are no items to show.

Search

Clear search

Close search

Google apps

Main menu

翻译：